The editors publish this note to make it explicit that the journal agreed to publish, “Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels” [Riordan, Hincapié, Morales, et al., STEM CELLS Translational Medicine 2019;8:1008-1016] after careful peer review and consideration. The editors publish this note to add transparency to the full disclosure of the study treatments and the participants' costs. Following the advice of their Institutional Review Board, the authors included in the informed consent and on ClinicalTrials.gov an estimate of out-of-pocket expenses that the participants might incur for transportation, lodging, and meals, none of which were expenses for the treatment. Based on the evidence provided, the editors consider that this explanation does not have a material impact on the article by Neil Riordan et al.

编辑发表此说明以明确表明该期刊同意发表“用于治疗儿童自闭症谱系障碍的异基因人类脐带间充质干细胞：安全概况和对细胞因子水平的影响”[Riordan, Hincapié, Morales, et al., STEM CELLS 转化医学2019;8:1008-1016] 经过仔细的同行评审和考虑。编辑发布此说明以增加研究治疗和参与者费用的全面披露的透明度。根据其机构审查委员会的建议，作者在知情同意书和 ClinicalTrials.gov 上包括了参与者可能因交通、住宿和膳食而产生的自付费用的估计，这些都不是试验的费用。治疗。根据所提供的证据，编辑认为这种解释对 Neil Riordan 等人的文章没有实质性影响。